EcoDrugPlus

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSMZEG00005020369
Gene Symbol: HTR2A
3 Cross references
189 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSMZEG00005017733
Gene Symbol: HTR2B
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSMZEG00005010453
Gene Symbol: HTR3A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSMZEG00005010442
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSMZEG00005004414
Gene Symbol: HTR4
3 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSMZEG00005022087
Gene Symbol: HTR5A
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSMZEG00005021663
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSMZEG00005027241
Gene Symbol: HTR7
3 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L10

Ensembl ID : ENSMZEG00005026532
Gene Symbol: LOC101464765
3 Cross references
384 Possible Orthologues:

60s Ribosomal Protein L14

Ensembl ID : ENSMZEG00005011770
Gene Symbol: LOC101482523
3 Cross references
303 Possible Orthologues:

60s Ribosomal Protein L14-Like

Ensembl ID : ENSMZEG00005009351
Gene Symbol: LOC112433820
3 Cross references
305 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSMZEG00005015716
Gene Symbol: LOC101480515
4 Cross references
338 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).